Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using Box-Behnken design and response surface methodology

References

• Alex MR, Chacko AJ, Jose S, Souto EB. 2011. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 42:11–18.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutical drug classification: the correlation in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12:413–420.
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 13:123–133.
   PubMed Web of Science ®Google Scholar
• Damia G, Dincalci M. 1995. Clinical pharmacokinetics of altretamine. Clin Pharmacokinet. 28:39–48.
   Web of Science ®Google Scholar
• Das S, Ng WK, Kanaujia P, Kim S. 2011. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: Effects of process variables. Colloid Surf B. 88:483–489.
   PubMed Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, Chowdhury P. 2010. Kinetic modelling on drug release from controlled drug delivery systems. Acta Pol Pharm. 67:217–223.
   PubMed Web of Science ®Google Scholar
• Driscoll MC. 2002. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 15:405–415.
   PubMed Web of Science ®Google Scholar
• Gambhire MS, Bhalekar MR, Gambhire VM. 2011. Simvastatin loaded Solid lipid nanoparticles: formulation optimization using Box Behnken design, characterization and in vitro evaluation. Current Pharm Res. 1:157–164.
   Google Scholar
• Ghasemian E, Vatanara A, Najafabadi AR, Darabi M. 2013. Preparation, characterization and optimization of sildenafil citrate loaded PLGA nanoparticles by statistical factorial design. DARU J Pharm Sci. 21:68–78.
   Web of Science ®Google Scholar
• Gidwani B, Vyas A. 2014. Synthesis, characterization and application of Epichlorohydrin-β-cyclodextrin polymer. Colloid Surf B. 114:130–137.
   PubMed Web of Science ®Google Scholar
• Gidwani B, Vyas A. 2013. The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer. Artif Cells Nanomed Biotech. 1–7.
   Web of Science ®Google Scholar
• Hansen LA, Hughes TE. 1991. Altretamine. DICP. 25:146–152.
   PubMedGoogle Scholar
• Hariharan M, Price JC. 2002. Solvent, emulsifier and drug concentration factors in poly (D, L-lactic acid) microspheres containing hexamethylmelamine. J Microencapsul. 19:95–109.
   PubMed Web of Science ®Google Scholar
• Higuchi T. 1963. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 52:1145–1149.
   Google Scholar
• Khan AA, Mudassir J, Mohtar N. 2013. Advanced drug delivery to the lymphatic system: lipid-based nano formulations. Int J Nanomed. 8:2733–2744.
   PubMed Web of Science ®Google Scholar
• Kreilgard B, Higuchi T, Repta AJ. 1975. Complexation in formulation of parenteral solutions: solubilization of the cytotoxic agent hexamethylmelamine by complexation with gentisic acid species. J Pharma Sci. 64:1850–1855.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Perez MH, Lehr M, Maincent P. 2000. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm. 196:177–182.
   PubMed Web of Science ®Google Scholar
• Lewis GA, Mathieu D, Phan-Tan-Luu R. 1999. Pharmaceutical Experimental Design: Drugs and Pharmaceutical Sciences, Vol. 92, 1st ed. New York: Marcel Dekker, : p. 235.
   Google Scholar
• Liu CH, Wu CT. 2010. Optimization of nanostructured lipid carriers for lutein delivery. Colloid Surf A Physicochem Eng A. 353:149–156.
   Web of Science ®Google Scholar
• Martini S, Herrera ML. 2008. Physical properties of shortenings with low-trans fatty acids as affected by emulsifiers and storage conditions. Eur J Lipid Sci Technol. 110:172–182.
   Web of Science ®Google Scholar
• Muller RH, Shegokar R, Keck CM. 2011. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol. 3:207–227.
   Google Scholar
• Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, et al. 2009. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine. 5:184–191.
   PubMed Web of Science ®Google Scholar
• Porter C, Charman WN. 2001. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 50:S127–S147.
   PubMed Web of Science ®Google Scholar
• Rahman Z, Zidan S, Khan MA. 2010. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm. 76:127–137.
   PubMed Web of Science ®Google Scholar
• Shailesh S, Veena S, Vivek R, Patil U. 2012. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloid Surf B. 97:109–116.
   PubMed Web of Science ®Google Scholar
• Singh MR, Singh D, Saraf S. 2011. Formulation optimization of controlled delivery system for antihypertensive peptide using response surface methodology. Am J Drug Dis Dev. 1:174–187.
   Google Scholar
• Song KC, Lee HS, Choung IY, Cho KI, Choi EJ. 2006. The effect of type of organic phase solvents on the particle size of poly (D, L-lactide-co-glycolide) nanoparticles. Colloids Surf A Physicochem Eng Asp. 276:162–167.
   Web of Science ®Google Scholar
• Sun J, Deng Y, Wang S, Cao J, Gao X, Dong X. 2010. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization and in vivo evaluation. Drug Deliv. 17:164–170.
   PubMed Web of Science ®Google Scholar
• Thigpen T. 1987. Chemotherapy for advanced or recurrent gynaecologic cancer. Cancer. 60:2104–2116.
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 95:627–638.
   PubMed Web of Science ®Google Scholar
• Wiernik PH. 1992. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the eastern cooperative oncology group. Cancer Invest. 10:1–9.
   PubMed Web of Science ®Google Scholar
• Wolfgang M, Karsten M. 2001. Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliv Rev. 47: 165–196.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Li Y. 2007. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 59:491–504.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fan Y, Smith E. 2009. Experimental design for the optimization of lipid nanoparticles. J Pharm Sci. 98:1813–1819.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu J, Qioa H, Liu H, Ni J. 2010. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol. 197:120–128.
   Web of Science ®Google Scholar